META Pharmaceuticals Announces Key Advancement of MP-5342, a First-in-Class Oral LDH Inhibitor Targeting the Multi-Billion-Dollar IBD Market

　　【Pharmaceutical Network Product Information】Inflammatory Bowel Disease (IBD) is a chronic, immune-mediated inflammatory disease of the gastrointestinal tract with complex clinical manifestations. A large number of patients still have significant unmet clinical treatment needs. Data shows that the global IBD drug market size has exceeded 20 billion US dollars and is expected to increase from 29.57 billion US dollars in 2024 to 44.08 billion US dollars in 2032, with an annual compound growth rate (CAGR) of 5.8%.
 

Targeting the $10 billion IBD drug market, multinational pharmaceutical companies such as Merck, Roche, Sanofi, and AbbVie have long been positioned, while local pharmaceutical companies are also striving to catch up, with the R&D boom continuing to rise.
 

In February 2026, META Pharmaceuticals Inc., a company incubated by XtalPi, announced that its first clinical development candidate molecule MP-5342 for inflammatory bowel disease (IBD) has been identified. An IND application is expected to be submitted to regulatory authorities in the second half of 2026, with Phase I clinical trials to commence thereafter.
 

It is reported that MP-5342 is the world's first oral small-molecule lactate dehydrogenase (LDH) inhibitor, an oral, targeted anti-inflammatory therapy designed to alter the course of the disease, with the potential to become a First-in-class treatment. As the world’s first highly selective oral small-molecule LDH inhibitor with excellent in vivo drug-like properties, MP-5342 has demonstrated broad potential in treating autoimmune diseases, including inflammatory bowel disease (IBD), multiple sclerosis (MS), and primary biliary cholangitis (PBC).
 

The product was independently developed by META. Preclinical studies, including pharmaceutical science, pharmacology, and toxicology, are currently being actively advanced to prepare for the new drug clinical trial (IND) application.
 

Notably, MP-5342 is the second first-in-class drug pipeline co-developed by XtalPi and META Pharmaceuticals Inc. that is about to enter clinical development. Previously, with the AI+ technology from XtalPi...RobotEmpowered by the R&D platform, META's small molecule inhibitor for primary hyperoxaluria has been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) by the U.S. FDA. It is expected to complete the Investigational New Drug (IND) application and early clinical trials within the next year.
 

This progress once again strongly validates XtalPi's AI + robotics drug discovery platform's powerful capabilities in original innovation breakthroughs, efficient clinical translation, and technical reproducibility. With its unique platform technology advantages, XtalPi is broadly empowering the new generation of innovative drug research and development, systematically and at scale developing high-value pipeline assets for partners, and creating value for the industry.
 

Public information shows that META Pharmaceuticals Inc. is an innovative drug company focusing on the research and development of drugs for autoimmune and metabolic diseases. It was jointly incubated by XtalPi, a pioneer in AI-driven drug discovery, Forcefield Ventures, and IMO Ventures, with investments from TianTu Capital, Yae Capital, FangYuan Capital, New Industry Venture Capital, DeXun Investment, and BoPu Capital. Based on cutting-edge emerging biological theories, the company aims to effectively regulate immune system functions and other physiological system functions by modulating cellular metabolic activity. It focuses on developing safer and more effective treatments for autoimmune and metabolic diseases, emphasizing the R&D of first-in-class innovative drugs to provide urgently needed medications for patients worldwide.
 

XtalPi is an innovative R&D platform based on quantum physics, empowered by artificial intelligence, and driven by robotics. The company combines first-principles calculations based on quantum physics, artificial intelligence, high-performance cloud computing, and scalable and standardized robotic automation to provide drug and materials science R&D solutions and services for global and Chinese companies in industries such as pharmaceuticals and materials science (including agrotechnology, energy, new chemicals, and cosmetics).
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.